Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York. ‘Bluebird is an IPO from a few years ago and this company has had a really good run and completed a few offerings to keep ownership of their products in house,’ said Scott Smith, director of life sciences investment banking at Wedbush. ‘They’ve also had very good trial results, along with cutting edge science. The company is in its early stage but looks very promising.’ Shares are up a staggering 440 percent since the gene therapy company’s 2013 debut on the Nasdaq. Pacira Pharmaceuticals is also seeing heavy investor interest. ‘Pacira is in what I would call the specialty pharmacy space,’ Smith added. ‘They’ve really executed on the launch of their key product, Exparel,’ which is a local analgesic. He said the company has a fairly robust market capitalization of $2.3 billion. TheStreet's Scott Gamm reports from New York.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.